Enhancement of antipsychoticlike properties of raclopride in rats using the selective serotonin2A receptor antagonist MDL 100,907

被引:35
作者
Wadenberg, MLG
Hicks, PB
Richter, JT
Young, KA
机构
[1] Scott Sherwood & Brindley Fdn, Scott & White Clin & Mem Hosp, Dept Psychiat, Temple, TX USA
[2] Cent Texas Vet Hlth Care Syst, Neurosci Lab, Waco, TX USA
[3] Texas A&M Univ, Ctr Hlth Sci, Coll Med, College Stn, TX USA
基金
瑞典研究理事会; 英国医学研究理事会;
关键词
dopamine D(2) receptor; serotonin(2A) receptor; conditioned avoidance response behavior; atypical antipsychotic drugs; rat;
D O I
10.1016/S0006-3223(97)00424-1
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: Selective suppression of conditioned avoidance response (CAR) is a standard animal screening test for predicting antipsychotic effect Ability to suppress CAR is presumed to be due to antagonism at dopamine receptors, a property shared by all known antipsychotics, Methods: Using CAR behavior, in a conventional shuttle-box paradigm, as an index for antipsychotic efficacy, the effects of the selective serotonin, receptor antagonist MDL 100,907 alone, and in combination with the dopamine D(2) receptor antagonist raclopride, were studied in adult male Sprague-Dawley rats. Nonparametric procedures were employed for statistical evaluation. Results: MDL 100,907 (0.1-1.5 mg/kg, SC) alone did not suppress CAR in a manner predictive of antipsychotic activity: however, in the presence of an ED(50) (0.14 mg/kg, SC) dose of raclopride, MDL 100,907 enhanced and prolonged the suppression of CAR. In the presence of a subthreshold (0.05 mg/kg, SC) dose of raclopride, MDL 100,907 induced a suppression of CAR. Conclusions: The results suggest that treatment with a selective serotonin(2A) receptor antagonist alone may nor produce a robust antipsychotic effect; however, a selective serotonin(2A) receptor antagonist in the presence of a minimal dopamine D(2) receptor blocking action could potentially be an adjunctive therapy resulting in improved antipsychotic efficacy and fewer extrapyramidal symptoms. (C) 1998 Society of Biological Psychiatry.
引用
收藏
页码:508 / 515
页数:8
相关论文
共 40 条
[1]  
ANDERSSON JL, 1995, N-S ARCH PHARMACOL, V352, P374
[2]  
ARNT J, 1982, ACTA PHARMACOL TOX, V51, P321
[3]  
Ayd F J Jr, 1982, Mod Probl Pharmacopsychiatry, V18, P49
[4]  
Baldessarini R., 1996, GOODMAN GILMANS PHAR, P399
[5]   RISPERIDONE IN THE TREATMENT OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA - A METAANALYSIS [J].
CARMAN, J ;
PEUSKENS, J ;
VANGENEUGDEN, A .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1995, 10 (04) :207-213
[6]  
Courvoisier S., 1957, PSYCHOTROPIC DRUGS, P373
[7]  
COURVOISIER SIMONE, 1956, JOUR CLIN AND EXPTL PSYCHOPATH AND QUART REV PSYCHIATRY AND NEUROL, V17, P25
[8]   DIFFERENTIAL EFFECTS OF NEUROLEPTIC AND OTHER PSYCHOTROPIC AGENTS ON ACQUISITION OF AVOIDANCE IN RATS [J].
DAVIDSON, AB ;
WEIDLEY, E .
LIFE SCIENCES, 1976, 18 (11) :1279-1284
[9]  
DUDLEY M, 1990, Society for Neuroscience Abstracts, V16, P1037
[10]   RITANSERIN, A SELECTIVE 5-HT(2/1C) ANTAGONIST, AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA - A PLACEBO-CONTROLLED DOUBLE-BLIND TRIAL [J].
DUINKERKE, SJ ;
BOTTER, PA ;
JANSEN, AAI ;
VANDONGEN, PAM ;
VANHAAFTEN, AJ ;
BOOM, AJ ;
VANLAARHOVEN, JHM ;
BUSARD, HLSM .
BRITISH JOURNAL OF PSYCHIATRY, 1993, 163 :451-455